NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

000251-C

Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 120 Years

Referral Letter Required

No

Population Exclusion(s)

Pregnant Women;
Neonates;
Non-English Speaking;
Children

Keywords

Ipilimumab;
Pembrolizumab;
relatlimab;
nivolumab;
Lymphocyte activation gene 3;
LAG-3;
Garmin;
anti PD-1/PD-L1;
Acceptance and Commitment Training (ACT)

Recruitment Keyword(s)

None

Condition(s)

Melanoma

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

Behavioral: Intervention Arm
Behavioral: Control

Supporting Site

National Cancer Institute

Background:

The gut microbiome is made up microorganisms. These include the good and bad bacteria that live in the digestive tract. Changes in the gut microbiome have been linked to the development of cancer. Researchers want to learn more about the effects of modulating the microbiome with diet and exercise.

Objective:

To see if nutritional intake and physical activity change the gut microbiome in people with melanoma.

Eligibility:

Adults age 18 and older with previously untreated melanoma who will be getting immunotherapy treatment for their disease.

Design:

Participants will not have visits at NIH. They will have phone calls or videocalls.

Participants will be screened with a medical history and medical record review.

Participants will give stool samples. They will fill out surveys about their health, feelings, diet, and exercise.

Participants will be put in 1 of 2 groups. They will follow their group s plan for 4 months. They will be contacted throughout the study.

Intervention Group participants will follow a plant-based, high-fiber diet. They will do at least 150 minutes of moderate or 75 minutes of high-intensity exercise per week. They will have sessions with psychology staff to help them make positive lifestyle changes.

Control Group participants will be taught healthy eating and exercise guidelines. But they will not be asked to change their diet or exercise habits.

All participants will record what they eat in the MyFitnessPal app. They will get a scale to measure their weight each week. They will wear a Garmin(R) physical activity tracker at all times. They can take the tracker off to bathe or shower.

Participation will last for 6 months.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

-Participants must have histologically or cytologically confirmed melanoma that has not been treated with any systemic therapy in the past 30 days.

-Participants must be planning to undergo immunotherapy treatment with one of the following options: ipilimumab and nivolumab, relatlimab and nivolumab, pembrolizumab, or nivolumab. Note: This treatment is permissible to have started up to 14 days prior to completion of baseline assessments on this study to still be eligible for enrollment.

-Age >= 18 years and English speaking. English-language ability is required because a portion of the study involves reading and responding to English-language questionnaires, along with creating a free response spoken answer to a question, where the information will be transcribed and analyzed.

-Willingness and capability to comply with diet and exercise prescriptions, use the MyFitnessPal app, wear the Garmin (trademark) device, complete surveys, and provide stool samples. Participants must own a smartphone capable of running the MyFitnessPal and Garmin Connect (trademark) apps.

-ECOG performance status <=2 (Karnofsky >60%).

-The ability of the subject to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

-Participants who are receiving any investigational agents other than relatlimab or nivolumab

-Any concurrent malignancy that requires active systemic therapy

-Any health condition that requires treatment with cytotoxic chemotherapy or targeted therapy

-Medical contraindications to the study diet and/or exercise prescriptions as determined by a physician

-Self-reported dietary and/or exercise restrictions that would preclude adherence to the study diet and exercise prescriptions

-Systemic antibiotic use within the past 30 days

-Use of probiotic supplements (probiotic foods such as yogurt, kefir, sauerkraut, etc., are permissible), fiber supplements, bile acid

sequestrants, weight loss supplements, or appetite suppressants within the last 30 days.

-Women known to be pregnant or lactating are excluded from the study because it is unknown if the study diet and exercise prescriptions may have deleterious effects on the child and/or mother in the context of pregnancy/breastfeeding.

-Current smoker or < 8 weeks since smoking cessation. There is evidence that smoking may alter the microbiome.

-Heavy drinker defined as >14 alcoholic drinks per week

-Current illicit drug use. There is evidence that illicit drug use may alter the microbiome.

-Diagnosis of diabetes mellitus type I or II that requires treatment

-Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

James L. Gulley, M.D.
National Cancer Institute (NCI)
NIHBC 10 - CLINICAL CENTER BG RM 13N240C
10 CENTER DR
BETHESDA MD 20892
(301) 480-7164
gulleyj@mail.nih.gov

Katherine O. Lee-Wisdom, R.N.
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 13N240
10 Center Drive
Bethesda, Maryland 20892
(240) 858-3525
katherine.lee-wisdom@nih.gov

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
1-888-NCI-1937

Clinical Trials Number:

NCT04866810

--Back to Top--